Compounds > 3'-fluoro-3'-deoxyadenosine
Page last updated: 2024-12-07

3'-fluoro-3'-deoxyadenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3'-fluoro-3'-deoxyadenosine (3'-F-dAdo) is a nucleoside analog that has been investigated for its potential antiviral and anticancer properties. It is a synthetic compound that is structurally similar to adenosine, a naturally occurring nucleoside. The fluorine atom at the 3' position of the sugar moiety disrupts the normal function of the nucleoside, leading to its biological activity. 3'-F-dAdo has shown inhibitory activity against various viruses, including HIV and hepatitis C virus. It is also known to inhibit DNA polymerase and ribonucleotide reductase, enzymes involved in DNA synthesis and replication, thus contributing to its anticancer potential. The compound has been investigated for its ability to overcome drug resistance in cancer cells and is currently being explored in preclinical studies.'
```

3'-fluoro-3'-deoxyadenosine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122619
CHEMBL ID72928
SCHEMBL ID969050
MeSH IDM0174042

Synonyms (20)

Synonym
CHEMBL72928 ,
3'f-3'da
(2r,3s,4s,5r)-2-(6-aminopurin-9-yl)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-3-ol
3'-fluoro-3'-deoxyadenosine
adenosine, 3'-deoxy-3'-fluoro-
75059-22-2
bdbm50144933
(2r,3s,4s,5r)-4-fluoro-5-hydroxymethyl-2-(6-methylamino-purin-9-yl)-tetrahydro-furan-3-ol
3'-deoxy-3'-fluoroadenosine
(2r,3s,4s,5r)-2-(6-aminopurin-9-yl)-4-fluoro-5-(hydroxymethyl)oxolan-3-ol
3'-f-da
(2s,3r,4r,5s)-2-(6-amino-9h-purin-9-yl)-4-fluoro-5-(hydroxymethyl)-tetrahydrofuran-3-ol
DTXSID70226033
(2r,3s,4s,5r)-2-(6-amino-9h-purin-9-yl)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-3-ol
SCHEMBL969050
AC-32287
AKOS027324855
mfcd20134043
F13576
DS-11561
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RNA-directed RNA polymerase IC50 (µMol)28.00000.01902.52798.8000AID86858
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H1 receptorCavia porcellus (domestic guinea pig)EC50 (µMol)1.20000.00260.53341.2020AID86857
RNA-directed RNA polymerase EC50 (µMol)1.20000.00180.23482.8000AID86857
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID218041Concentration (MIC), which is required to reduce virus-induced cytopathogenicity in African green monkey kidney (Vero B) cells against Sindbis virus1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID86857Inhibition HCV RNA replication2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
AID1757145Antitrypanosomal activity against Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 cells assessed as inhibition of parasite growth incubated for 7 days by chlorophenol red-fl-D-galactopyranoside based spectrophotometric analysis2021European journal of medicinal chemistry, Apr-15, Volume: 216Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
AID1757142Antileishmanial activity against Leishmania infantum MHOM/MA(BE)/67 infected in mouse primary peritoneal macrophages treated 2 hrs post-infection and incubated for 5 days by Giemsa staining based microscopic analysis2021European journal of medicinal chemistry, Apr-15, Volume: 216Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
AID218037Concentration (MIC), which is required to reduce virus-induced cytopathogenicity in African green monkey kidney (Vero B) cells against Coxsackie virus-B41991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID218040Concentration (MIC), which is required to reduce virus-induced cytopathogenicity in African green monkey kidney (Vero B) cells against forest virus1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID86858Inhibition HCV NS5B-mediated RNA synthesis2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
AID1757148Selectivity index, ratio of EC50 for human MRC5 cells to EC50 for antitrypanosomal activity against Trypanosoma brucei brucei2021European journal of medicinal chemistry, Apr-15, Volume: 216Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
AID91267Concentration required to reduce the viability of Human B-lymphoblast Raji cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID156711Concentration (MIC), required to reduce virus-induced cytopathogenicity in HeLa cells of Primary rabbit kidney (PRK ) cells against Vesicular stomatitis virus type 11991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID87150Concentration (MIC), which is required to reduce virus-induced cytopathogenicity in HeLa cells against Polio virus type-11991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID156717Concentration (MIC)required to reduce virus-induced cytopathogenicity in Primary rabbit kidney (PRK ) cells against HSV-1 with a strain KOS1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID662566Growth inhibition of Trichomonas vaginalis T1 after 24 hrs by hemocytometry2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
S-Adenosylhomocysteine hydrolase of the protozoan parasite Trichomonas vaginalis: potent inhibitory activity of 9-(2-deoxy-2-fluoro-β,D-arabinofuranosyl)adenine.
AID662565Growth inhibition of Trichomonas vaginalis T1 at 100 uM after 24 hrs by hemocytometry2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
S-Adenosylhomocysteine hydrolase of the protozoan parasite Trichomonas vaginalis: potent inhibitory activity of 9-(2-deoxy-2-fluoro-β,D-arabinofuranosyl)adenine.
AID1757141Cytotoxicity against mouse primary macrophage cells assessed as reduction in cell viability2021European journal of medicinal chemistry, Apr-15, Volume: 216Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
AID156839Concentration (MIC)required to reduce virus-induced cytopathogenicity in Primary rabbit kidney (PRK ) cells against HSV-2 with a strain G1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID218042Concentration (MIC), which is required to reduce virus-induced cytopathogenicity in African green monkey kidney (Vero B) cells against para-influenza virus-31991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID89805Concentration required to reduce the viability of Human T-lymphoblast MT-4 cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID218034Concentration (MCC) required to cause a microscopically detectable alteration of normal cell morphology, African green monkey kidney (Vero B) cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID156714Concentration (MIC), required to reduce virus-induced cytopathogenicity in Primary rabbit kidney (PRK ) cells against Vesicular stomatitis virus type 21991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID1167621Antiviral activity against Hepatitis C virus infected in mouse HB-1 cells after 24 hrs by ribonuclease replicon assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
AID142337Concentration required to reduce the viability of Murine leukemia L1210 cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID1757144Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 3 days by resazurin dye based fluorimetric analysis2021European journal of medicinal chemistry, Apr-15, Volume: 216Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
AID89806Concentration required to reduce the viability of Human T-lymphoblast Molt/4F cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID1757147Antitrypanosomal activity against Trypanosoma brucei rhodesiense assessed as parasite growth inhibition2021European journal of medicinal chemistry, Apr-15, Volume: 216Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
AID218039Concentration (MIC), which is required to reduce virus-induced cytopathogenicity in African green monkey kidney (Vero B) cells against Reo-virus-11991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID156695Concentration (MCC) required to cause a microscopically detectable alteration of normal cell morphology, in Primary rabbit kidney (PRK) cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID1757140Selectivity index, ratio of EC50 for cytotoxicity against mouse primary macrophage to EC50 for antileishmanial activity against Leishmania infantum MHOM/MA(BE)/67 infected in mouse primary peritoneal macrophages2021European journal of medicinal chemistry, Apr-15, Volume: 216Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
AID1757143Selectivity index, ratio of EC50 for cytotoxicity against human MRC5 cells to EC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 cells2021European journal of medicinal chemistry, Apr-15, Volume: 216Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
AID87138Concentration (MCC) required to cause a microscopically detectable alteration of normal cell morphology, in HeLa cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID1757139Antitrypanosomal activity against Trypanosoma brucei brucei assessed as parasite growth inhibition2021European journal of medicinal chemistry, Apr-15, Volume: 216Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
AID156716Concentration (MIC), which is required to reduce virus-induced cytopathogenicity in Primary rabbit kidney (PRK ) cells against Vaccinia virus1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases.
AID1757149Selectivity index, ratio of EC50 for human MRC5 cells to EC50 for antitrypanosomal activity against Trypanosoma brucei rhodesiense2021European journal of medicinal chemistry, Apr-15, Volume: 216Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's4 (36.36)18.2507
2000's2 (18.18)29.6817
2010's2 (18.18)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.59 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		2.3110phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		2.0710C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		2.3110antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
cordycepin
[no description available]		2.75303'-deoxyribonucleoside;
adenosines		antimetabolite;
nucleoside antibiotic
2'-deoxyadenosine
2'-deoxyformycin A: RN not in Chemline 9/85; RN and structure given in first source		2.0710purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
dideoxyadenosine
Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.		2.0110adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		2.4420beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.3110C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
ribavirin
Rebetron: Rebetron is tradename		2.1101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		2.0710adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
phosphoramidic acid
phosphoramidic acid: urease inhibitor; RN given refers to parent cpd; structure; do not confuse with phosphoramidites, which are organophosphorus compounds		2.0110phosphoric acid derivative
2-aminoadenosine
[no description available]		2.0710purine nucleoside
adenosine 2',3'-ribo-epoxide
adenosine 2',3'-ribo-epoxide: structure		2.0710
2'-fluoro-2'-deoxyadenosine
[no description available]		2.4420
2'-o-methyladenosine
cordysinin B : A member of the class of adenosines that is adenosine in which the hydroxy group at position 2' is replaced by a methoxy group. It has been isolated from the mycelia of Cordyceps sinensis.		2.0210adenosines;
ether		fungal metabolite
adenylyl-(2'-5')-adenylyl-(2'-5')adenosine
adenylyl-(2'-5')-adenylyl-(2'-5')adenosine: inhibits protein synthesis in intact mouse lymphocytes, hepatocytes & bone marrow cells		1.9810
5'-deoxy-5'-s-isobutylthioadenosine
5'-deoxy-5'-S-isobutylthioadenosine: considered an analog of S-adenosylhomocysteine; structure		2.0710
3'-c-methyladenosine
3'-C-methyladenosine: structure in first source		2.0210
2'-c-methyladenosine
2'-C-methyladenosine: antiviral		2.0210
5'-chloro-5'-deoxyadenosine
[no description available]		2.0710adenosines
2'-amino-2'-deoxyuridine
2'-amino-2'-deoxyuridine: structure in first source		2.0710
5'-amino-5'-deoxyadenosine
[no description available]		2.0710
sofosbuvir
Sofosbuvir: A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.. sofosbuvir : A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.		2.110isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug
inosine
[no description available]		2.0710inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2'-o-methylguanosine
2'-O-methylguanosine : Guanosine with the hydrogen on the hydroxyl at position C-2' substituted with a methyl group.		2.0210methylguanosinemetabolite
2'-deoxy-2'-fluoroguanosine
2'-deoxy-2'-fluoroguanosine: has activity in human respiratory epithelial cells against both influenza A & B viruses		2.0210
3-deoxyguanosine
3'-deoxyguanosine : A 3'-deoxyribonucleoside having guanine as the nucleobase.		2.02103'-deoxyribonucleoside;
guanosines		EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9710
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
[description not available]		02.110
Hepatitis C
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.		02.110
Congenital Zika Syndrome
[description not available]		02.3110
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.3110
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.0110
Vaccinia
The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.		01.9710